Category Archives: HIV care & treatment
Some good news for people on ADAP waiting lists
In a statement issued today by NASTAD, the HIV drug assistance program run by Welvista will transition to a new organization called HarborPath effective May 6, 2013. The Welvista program currently helps uninsured and under-insured individuals ineligible for ADAP or on ADAP waiting lists get their…Read More
CROI2013: Experimental treatments for HIV
At this year’s Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta there were several presentations about new treatments or new treatment strategies that could benefit both those new to treatment as well as treatment veterans. Merck presented data on a new non-nucleoside reverse transcriptase (NNRTI)…Read More
Project Inform issues recommendations on using surveillance data for HIV care linkage and retention
Read the full report online. SAN FRANCISCO, April 1, 2013. Project Inform, an HIV and hepatitis advocacy and education group has published recommendations drafted by a diverse group of advocates and public health professionals guiding the use of laboratory data collected by public health surveillance agencies to…Read More
CROI2013: HIV and your heart
There were a number of presentations and posters on HIV and the heart this year at the Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. These ranged from studies showing that a common scoring system for heart attack risk may under-estimate risk in people with…Read More
Recently, Anthem Blue Cross announced that it would require some of its plan subscribers to use a mail order pharmacy to obtain their medications. Specifically, those who depend on what Anthem has termed as “specialty drugs”, including HIV treatments. Such individuals will now have to obtain…Read More
On February 12, just in time for Valentine’s Day, the U.S. Department of Health and Human Services (DHHS) antiretroviral treatment (ART) guidelines panel issued updates to their recommendations for when people living with HIV should start ART and which drugs are best to use, among other…Read More
Development of lersivirine stopped after promising phase 2 results
In a statement issued February 5, 2013, ViiV Healthcare announced they were halting the development of their new NNRTI lersivirine. This comes on the heals of promising 48-week results released from a phase IIb study that compared lersivirine to efavirenz (Sustiva). That study showed lersivirine controlled…Read More